Pioneering the pharmaceutical industry psyrusamine to prevent the transformation of symptoms in patients with new crowns was significantly effective for both men and women

On January 10, 2021, Pioneer Pharmaceuticals released interim data on its new crown female subjects for psyruline therapy in Brazil.
Interim data on the treatment of female subjects with new crowns, consistent with the results of clinical trials previously published for the treatment of new crown male subjects, significantly reduced the conversion from mild to severe in new crown patients, demonstrating that there may be no gender difference in the efficacy of psyrus in the treatment of new crown patients.
is a new generation of androgen-infested (AR) antagonists developed by pioneering the pharmaceutical industry.
Pructramine Therapeutic New Crown Clinical Trial (NCT04446429) is a randomized, double-blind and placebo-controlled clinical trial designed to explore the effectiveness of psyrusamine in treating new crown patients, speeding up patient-positive trans negatives and preventing the transition from mild to severe by inhibiting viral replication and reproduction.
main endpoints included the percentage of subjects admitted to hospital with the new crown within 30 days and the clinical symptom assessment.
December 11, 2020, Pioneer Pharmaceuticals announced the preliminary clinical results of the treatment of new crown male subjects.
January 7, 2021, Pioneer Pharmaceuticals released final data for the clinical trial.
results showed that psyruamine significantly inhibited the conversion of newly crowned male subjects from mild to severe, and that short-term medication (15 days of oral use) was safe.
The final clinical trial results of the new crown male subjects included data from 134 subjects in the psyruamine treatment group and 128 subjects in the placebo control group, showing that no subjects in the psyruline treatment group were hospitalized with a hospitalization rate of 0%, while 35 subjects in the control group deteriorated and were hospitalized at a rate of 27%.
was significantly reduced in hospitalization in male subjects with new crowns, and no adverse events associated with psyruamine were observed during the study period.
In November 2020, based on positive results demonstrated by the new crown male subjects of psyruamine therapy, the Brazilian government health department recommended that pioneering the pharmaceutical industry continue to work with clinical researchers in the United States and Brazil to initiate clinical trials of the new crown female subjects.
The trial program included 168 new crown female subjects, all menopedal women over the age of 50 who tested positive for nucleic acid within 7 days and had new coronary symptoms, were included in the "pruamine plus standard treatment" trial group and the control group received "placebo plus standard treatment" on a 2:1 scale, with a protrusion treatment cycle of 15 days after joining the group.
time, the interim data published by Pioneer Pharmaceuticals for female subjects to the new crown of psyruamine treatment included data from 60 psyroamine treatment groups and 35 placebo control group subjects (as of January 7, 2021), showing a hospitalization rate of 1.6% in the pro cruminide treatment group. 7%, ICU use percentage is 0%, use ventilator percentage is 0%, mortality rate is 0%, compared with 17.1% hospitalization rate, ICU use percentage is 8.6%, use ventilator percentage is 5.7%, mortality rate is 2.9%.
clinical trial results for female subjects treated with psyruamine are expected to be announced in Q1 2021.
the interim data of the treatment of female subjects with psalmruamine were effective in treating both male and female subjects of the new crown, and the results were significant.
Because it is generally accepted that women's androgen androgen receptors have lower levels of expression than men's, whether androgen signaling pathsters play a role in viral infections in female newly crowned patients is consistent with that in men is still worth studying.
The pioneering pharmaceutical industry has now seen in clinical trials that the efficacy of psyruamine in treating new crown female subjects is similar to that of men, which not only increases the population in which psyrata is effective in treating patients, but also further strengthens the effectiveness of psyruamine in treating new crown patients.
Pioneer Pharmaceuticals plans to launch clinical trials in Brazil as soon as possible for the treatment of new patients with severe hospitalization, apply for emergency drug licensing, and conduct Phase III clinical trials of international MRCT to benefit more new crown patients as soon as possible.